Prognostic Value of Immunohistochemical Staining of p53, bcl-2, and Ki-67 in Small Cell Lung Cancer

Paik, Kwang Hyun; Park, Yeon Hee; Ryoo, Baek‐Yeol; Yang, Sung Hyun; Lee, Jae Cheol; Kim, Cheol Hyun; Ki, Seung Seog; Kim, Jung Min; Park, Myung Joon; Ahn, Heui June; Choi, Won Ku; Chung, Jin Haeng

doi:10.3346/jkms.2006.21.1.35

Cited by 23 publications

(23 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As p53 is the most commonly mutated gene in human cancer, including lung squamous cell carcinoma, it has attracted a great deal of interest as a prognostic factor, diagnostic tool and therapeutic target [17]. Recent studies using immunohistochemical staining following antigen retrieval investigated the expression of p53 in 45 patients with non-small cell lung carcinomas and found that 40% of the tumors demonstrated positive of p53.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The expression of GST isoenzymes and p53 in non-small cell lung cancer.

Oğuztüzün¹,

Aydın²,

Demırağ³

et al. 2010

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

This study investigated the immunohistochemical staining characteristics of glutathione-S-transferase alpha, pi, mu, theta and p53 in non-small cell lung carcinoma and normal lung tissue from 50 patients. The relationships between expressions of the Glutathione-S-transferase isoenzymes and some clinicopathological features were also examined. Expression of glutathione-S-transferase pi, mu, alpha, theta and p53 was assessed by immunohistochemistry for primary lung carcinomas of 50 patients from the Sanitarium Education and Research Hospital, Ankara lung cancer collection. The relationships between expression of the glutathione-S-transferase isoenzymes, p53 in normal and tumor tissue by Student T test and the clinicopathological data were also examined by Spearman Rank tests. When the normal and tumor tissue of these cases were compared according to their staining intensity and percentage of positive staining, glutathione-S-transferase alpha, pi, mu, theta expressions in tumor cells was significantly higher than normal cells (p<0.05). There was no significant difference in the expression of p53 between normal and tumor cells (p>0.05). When the immunohistochemical results of glutathione-S-transferase isoenzymes and p53 were correlated with the clinical parameters, there were no significant associations between glutathione-S-transferases and p53 expressions and tumor stage, tumor grade and smoking status (p>0.05).

show abstract

Section: Discussionmentioning

confidence: 99%

“…The expression rate of altered p53 tumor suppressor gene was relatively high in small cell lung cancer (SCLC) without any prognostic significance [17].…”

Section: Introductionmentioning

confidence: 99%

The expression of GST isoenzymes and p53 in non-small cell lung cancer.

Oğuztüzün¹,

Aydın²,

Demırağ³

et al. 2010

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

show abstract

“…In fact, Bcl-2 overexpression, mainly with nuclear localization, together with a high Bcl-2/Bax ratio, was correlated directly with an elevated spontaneous apoptosis index (31)(32)(33), and with the absence of metastasis in SCLC tumors (34). The relationship between Bcl-2 overexpression and tumor stage is less clear, but an inverse correlation between Bcl-2 levels and cancer progression has already been pointed out (29,(34)(35)(36). In addition, there are cases of reduced Bcl-2 levels upon in vitro acquisition of resistance to cisplatin (37).…”

Section: Discussionmentioning

confidence: 97%

“…Nevertheless, despite controversial data, existing evidence about the specific role of Bcl-2 in SCLC is consistent with the results obtained in the present study. It has been demonstrated that, regardless of the frequently observed Bcl-2 overexpression in SCLC cell lines (2) and tumors (3), there is no correlation between Bcl-2 expression and resistance to therapy and/or patient survival (26)(27)(28)(29)(30). In fact, Bcl-2 overexpression, mainly with nuclear localization, together with a high Bcl-2/Bax ratio, was correlated directly with an elevated spontaneous apoptosis index (31)(32)(33), and with the absence of metastasis in SCLC tumors (34).…”

Section: Discussionmentioning

confidence: 99%

In vitro modulation of Bcl-2 levels in small cell lung cancer cells: effects on cell viability

Santos

Pereira

Lima

et al. 2010

Braz J Med Biol Res

View full text Add to dashboard Cite

“…This high degree of variability of cell cycle components and their regulators in SCLC makes the predictions about response to cell cycledirected agents very complex. Almost 60% to 80% of the SCLC patients express abnormal p53 without any chemotherapy response correlation or prognostic significance (33) and in vitro, wild-type p53 restoration does not modify the sensitivity of a lung cancer cell line to a given chemotherapeutic agent (34). Flavopiridol is known to induce apoptosis in certain cell types independent of Rb and p53 pathway alterations (35,36).…”

Section: Discussionmentioning

confidence: 99%

Retinoblastoma Tumor Suppressor Gene Expression Determines the Response to Sequential Flavopiridol and Doxorubicin Treatment in Small-Cell Lung Carcinoma

Budak‐Alpdoğan

Chen

Warrier

et al. 2009

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Small-cell lung cancers (SCLC) are defective in many regulatory mechanisms that control cell cycle progression, i.e., functional retinoblastoma protein (pRb). Flavopiridol inhibits proliferation and induces apoptosis in SCLC cell lines.We hypothesized that the sequence flavopiridol followed by doxorubicin would be synergistic in pRb-deficient SCLC cells. Experimental Design: A H69 pRb-deficient SCLC cell line, H865, with functional pRb and H865 pRb small interfering RNA (siRNA) knockdown cells were used for in vitro and in vivo experiments. The in vivo efficiencies of various sequential combinations were tested using nude/ nude athymic mice and human SCLC xenograft models. Results: Flavopiridol then doxorubicin sequential treatment was synergistic in the pRB-negative H69 cell line. By knocking down pRb with specific siRNA, H865 clones with complete pRb knockdown became sensitive to flavopiridol and doxorubicin combinations. pRb-deficient SCLC cell lines were highly sensitive to flavopiridol-induced apoptosis. pRb-positive H865 cells arrested in G 0 -G 1 with flavopiridol exposure, whereas doxorubicin and all flavopiridol/doxorubicin combinations caused a G 2 -M block. In contrast, pRb-negative SCLC cells did not arrest in G 0 -G 1 with flavopiridol exposure. Flavopiridol treatment alone did not have an in vivo antitumor effect, but sequential flavopiridol followed by doxorubicin treatment provided tumor growth control and a survival advantage in Rb-negative xenograft models, compared with the other sequential treatments. Conclusions: Flavopiridol and doxorubicin sequential treatment induces potent in vitro and in vivo synergism in pRb-negative SCLC cells and should be clinically tested in tumors lacking functional pRB.

show abstract

Prognostic Value of Immunohistochemical Staining of p53, bcl-2, and Ki-67 in Small Cell Lung Cancer

Cited by 23 publications

References 33 publications

The expression of GST isoenzymes and p53 in non-small cell lung cancer.

The expression of GST isoenzymes and p53 in non-small cell lung cancer.

In vitro modulation of Bcl-2 levels in small cell lung cancer cells: effects on cell viability

Retinoblastoma Tumor Suppressor Gene Expression Determines the Response to Sequential Flavopiridol and Doxorubicin Treatment in Small-Cell Lung Carcinoma

Contact Info

Product

Resources

About